Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung

BACKGROUND: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the ALK gene....

Full description

Saved in:
Bibliographic Details
Published in:Surg Case Rep
Main Authors: Imanishi, Naoko, Yoneda, Kazue, Taira, Akihiro, Ichiki, Yoshinobu, Sato, Naoko, Hisaoka, Masanori, Tanaka, Fumihiro
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2018
Subjects:
Case Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845085/
https://ncbi.nlm.nih.gov/pubmed/29524063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-018-0430-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items